Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Type: Oral
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Sunday, December 8, 2024: 10:30 AM
Disclosures: Grosso: Tevogen Bio: Current Employment. Flomenberg: Tevogen Bio: Current Employment. Gergis: Moderna: Current equity holder in publicly-traded company; Iovance: Current equity holder in publicly-traded company; Kite: Other: Travel Support, Speakers Bureau; Astellas: Other: Travel Support, Speakers Bureau; Autolus: Consultancy; Incyte: Other: Travel Support, Speakers Bureau; VOR: Consultancy; Biontech: Current equity holder in publicly-traded company; Jazz: Other: Travel Support, Speakers Bureau.